Zacks Investment Research downgraded Quotient Ltd (NASDAQ:QTNT) to Sell in a statement released earlier today.
- Updated: October 15, 2016
Zacks Investment Research has downgraded Quotient Ltd (NASDAQ:QTNT) to Sell in a statement released on Wednesday October 12, 2016.
On 8/11/2015, Jefferies released a statement for Quotient Ltd (NASDAQ:QTNT) bumped up the target price from $0.00 to $30.00 that suggested an upside of 0%.
Boasting a price of $7.59, Quotient Ltd (NASDAQ:QTNT) traded 2.42% higher on the day. With the last stock price close down -7.67% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Quotient Ltd has recorded a 50-day average of $7.44 and a two hundred day average of $8.25. Volume of trade was down over the average, with 27,471 shares of QTNT changing hands under the typical 65,477
See Chart Below
Quotient Ltd has a 52 week low of $5.67 and a 52 week high of $17.44 The company’s market cap is currently $0.
General Information About Quotient Ltd (NASDAQ:QTNT)
Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market. It is engaged in developing MosaiQ, which is its technology platform. The Company develops, manufactures and commercializes the products, including antisera products, reagent red blood cells, whole blood controls and ancillary products. Its antisera products contain antibodies used to identify blood group antigens. Its antisera products are monoclonal antibodies manufactured from master cell lines it owns. Its reagent red blood cells products are composed of human red blood cells formulated to enable the identification of blood group antibodies. The Company develops, manufactures and sells conventional reagent products to original equipment manufacturers (OEMs).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.